<p>马萨诸塞州哈德逊和以色列约克尼姆，2026 年 5 月 11 日（环球新闻通讯社）——Lifeward Ltd.（纳斯达克代码：LFWD）（“Lifeward” 或 “公司”）是一家多元化的生物医学创新公司，拥有一系列商业化的神经康复产品和生物医学管道，今天宣布公司将在 2026 年 5 月 15 日星期五美国市场开盘前发布其 2026 年第一季度财务业绩。</p>
<p>在新闻发布后，公司的总裁兼首席执行官 Mark Grant 和首席财务官 Almog Adar 将于东部时间上午 8:30 召开电话会议和直播网络研讨会，讨论财务业绩。分析师和投资者可以使用以下方式访问会议：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>免费电话（美国）</td>
<td>1-833-316-0561</td>
</tr>
<tr>
<td>国际（美国以外）</td>
<td>1-412-317-0690</td>
</tr>
<tr>
<td>德国</td>
<td>0800-6647650</td>
</tr>
<tr>
<td>以色列</td>
<td>1-80-9212373</td>
</tr>
<tr>
<td>访问代码</td>
<td>请提及 “Lifeward 收益电话会议”</td>
</tr>
</tbody>
</table>
<p>电话会议将进行现场直播，并可通过公司网站 golifeward.com 的 “投资者” 部分的链接访问，或通过以下链接访问：https://edge.media-server.com/mmc/p/rz8f7ck8。公司网站的投资者活动日历页面也将提供存档的网络研讨会。</p>
<p><strong>关于 Lifeward</strong></p>
<p>Lifeward 是一家全球创新者，专注于推进改善生活的医疗技术和生物医学解决方案。公司的既有产品组合包括市场领先的神经康复技术，如 ReWalk®外骨骼、AlterG®抗重力系统、MyoCycle®功能性电刺激系统和 ReStore®外骨骼套件。这些解决方案涵盖了物理康复和恢复的整个护理过程，利用最先进的机器人和人工智能技术，恢复广泛患者群体的健康和生活质量。公司目前正在执行战略转型，成为一家多元化的生物医学公司，扩展到高价值的治疗平台。这包括其蛋白质口服递送（POD™）平台，旨在实现生物药物的口服递送，主要候选药物 ORMD-0801（口服胰岛素）针对一个庞大且未被充分服务的糖尿病市场。</p>
<p>Lifeward 在美国、以色列和德国开展业务。有关 Lifeward 使命和产品组合的更多信息，请访问 GoLifeward.com。</p>
<p>Lifeward®、ReWalk®、ReStore®和 Alter G®是 Lifeward Ltd.及其附属公司的注册商标。</p>
<p><strong>前瞻性声明</strong></p>
<p>除了历史信息外，本新闻稿还包含根据 1995 年美国私人证券诉讼改革法案、1933 年美国证券法第 27A 条和 1934 年美国证券交易法第 21E 条的定义的前瞻性声明，涉及 Lifeward、Oramed、与 Oramed 的战略投资和合作协议（统称为 “交易”）及其他事项。这些前瞻性声明可能包括关于公司未来表现的预测以及其他非历史事实的声明，并且在某些情况下，可能会用 “预期”、“假设”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“未来”、“将”、“应该”、“会”、“寻求” 等类似词语或短语来识别。本新闻稿中包含的前瞻性声明基于管理层当前的预期，这些预期受到不确定性、风险和难以预测的情况变化的影响，其中许多超出了公司的控制范围。可能导致公司实际结果与前瞻性声明中所示结果显著不同的重要因素包括但不限于：Lifeward 管理团队对未来的期望、希望、信念、意图或战略，包括但不限于关于交易的感知利益或机会的声明；关于收益使用的预期；Lifeward 未来的运营，包括研究和开发活动；Lifeward 的性质、战略和重点；预期的临床药物开发活动及相关时间表，以及其他临床结果；交易后资源的充足性，以支持 Lifeward 的管道通过某些里程碑的推进，以及 Lifeward 交易后资本资源将足以资助其预期运营的时间段；交易所导致的意外成本、费用或支出；交易所导致的潜在不利反应或商业关系变化；以及立法、监管、政治和经济发展；ReWalk 7 个人外骨骼被医疗专业人士和患者接受的情况；与未来临床试验和临床开发过程、产品开发过程以及 FDA 监管提交审查和批准过程相关的不确定性；公司是否有足够的资金满足某些未来资本需求，这可能会影响公司开发和商业化现有及新产品的努力；公司维护和提升其声誉及产品市场接受度的能力；公司从第三方支付方（包括 CMS）获得其产品报销的能力；公司有限的运营历史及其利用销售、市场营销和培训基础设施的能力；公司对其临床研究计划和临床结果的预期；公司对未来增长的预期，包括其在现有地理市场增加销售和扩展到新市场的能力；公司从第三方供应商获得其产品某些组件的能力及其对产品制造商的持续访问；公司在将其 AlterG 抗重力系统的生产转移到合同制造商以及将其 ReWalk 产品的制造转移到内部制造商时所面临的任何困难的应对能力；公司改善其产品和开发新产品的能力；公司遵守医疗器械报告法规以报告涉及公司产品的不良事件的能力，这可能导致自愿纠正措施或强制措施，例如强制召回，以及这些不良事件对公司市场和销售其产品能力的潜在影响；公司获得和维持监管批准的能力；公司维护其知识产权的充分保护并避免侵犯他人知识产权的能力；网络安全攻击或公司 IT 系统的漏洞显著干扰其业务运营的风险；公司有效使用其证券发行收益的能力；以及在公司向 SEC 提交的 2025 年 12 月 31 日结束的年度报告（修订版）及随后提交或提供给 SEC 的其他文件中 “风险因素” 标题下讨论的其他因素。本新闻稿中所做的任何前瞻性声明仅在此日期有效。可能导致公司实际结果与此处所含声明不同的因素或事件可能会不时出现，公司无法预测所有这些因素。除法律要求外，公司没有义务公开更新任何前瞻性声明，无论是由于新信息、未来发展还是其他原因。</p>
<p>联系方式：</p>
<p>Almog Adar</p>
<p>首席财务官</p>
<p>Lifeward</p>
<p>E: media@golifeward.com</p>
<p>E: ir@golifeward.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE56UXpOQ00zTlRrMU5ERTJJekl3TVRFeE9ETT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE56UXpOQ00zTlRrMU5ERTJJekl3TVRFeE9ETT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTc4NDIxMmItN2VjZC00ODhlLWJkN2ItZmZkMjA1ZWFjMjY4LTEwMjI3NTYtMjAyNi0wNS0xMS1lbg==/tiny/Lifeward-Ltd-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTc4NDIxMmItN2VjZC00ODhlLWJkN2ItZmZkMjA1ZWFjMjY4LTEwMjI3NTYtMjAyNi0wNS0xMS1lbg==/tiny/Lifeward-Ltd-.png"/></p>

LFWD

<p>Lifeward Ltd.（纳斯达克代码：LFWD）将于 2026 年 5 月 15 日美国市场开盘前公布其 2026 年第一季度财务业绩。公告后，首席执行官 Mark Grant 和首席财务官 Almog Adar 将于东部时间上午 8:30 召开电话会议，讨论业绩。Lifeward 是一家以神经康复产品闻名的生物医学创新公司，正在扩展其治疗平台，包括用于口服生物药物的蛋白质口服递送（POD™）平台。会议可以通过电话或公司网站访问</p>

<p>HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026.</p>
<div class="lb-trans"><p>马萨诸塞州哈德逊和以色列约克尼姆，2026 年 5 月 11 日（环球新闻通讯社）——Lifeward Ltd.（纳斯达克代码：LFWD）（“Lifeward” 或 “公司”）是一家多元化的生物医学创新公司，拥有一系列商业化的神经康复产品和生物医学管道，今天宣布公司将在 2026 年 5 月 15 日星期五美国市场开盘前发布其 2026 年第一季度财务业绩。</p>
</div><p>Following the news release, Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following:</p>
<div class="lb-trans"><p>在新闻发布后，公司的总裁兼首席执行官 Mark Grant 和首席财务官 Almog Adar 将于东部时间上午 8:30 召开电话会议和直播网络研讨会，讨论财务业绩。分析师和投资者可以使用以下方式访问会议：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Toll free (U.S.)</td>
<td>1-833-316-0561</td>
</tr>
<tr>
<td>International (Outside U.S.)</td>
<td>1-412-317-0690</td>
</tr>
<tr>
<td>Germany</td>
<td>0800-6647650</td>
</tr>
<tr>
<td>Israel</td>
<td>1-80-9212373</td>
</tr>
<tr>
<td>Access Code</td>
<td>Please reference the “Lifeward Earnings Call”</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>免费电话（美国）</td>
<td>1-833-316-0561</td>
</tr>
<tr>
<td>国际（美国以外）</td>
<td>1-412-317-0690</td>
</tr>
<tr>
<td>德国</td>
<td>0800-6647650</td>
</tr>
<tr>
<td>以色列</td>
<td>1-80-9212373</td>
</tr>
<tr>
<td>访问代码</td>
<td>请提及 “Lifeward 收益电话会议”</td>
</tr>
</tbody>
</table>
</div><p>The conference call will be webcast live and can be accessed through a link on the Company’s website at golifeward.com in the &#34;Investors&#34; section, or through the following link: https://edge.media-server.com/mmc/p/rz8f7ck8. An archived webcast will also be available on the Company's website at the Investor Events Calendar page.</p>
<div class="lb-trans"><p>电话会议将进行现场直播，并可通过公司网站 golifeward.com 的 “投资者” 部分的链接访问，或通过以下链接访问：https://edge.media-server.com/mmc/p/rz8f7ck8。公司网站的投资者活动日历页面也将提供存档的网络研讨会。</p>
</div><p><strong>About Lifeward</strong></p>
<div class="lb-trans"><p><strong>关于 Lifeward</strong></p>
</div><p>Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity system, MyoCycle® FES System, and ReStore® Exo-Suit. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market.</p>
<div class="lb-trans"><p>Lifeward 是一家全球创新者，专注于推进改善生活的医疗技术和生物医学解决方案。公司的既有产品组合包括市场领先的神经康复技术，如 ReWalk®外骨骼、AlterG®抗重力系统、MyoCycle®功能性电刺激系统和 ReStore®外骨骼套件。这些解决方案涵盖了物理康复和恢复的整个护理过程，利用最先进的机器人和人工智能技术，恢复广泛患者群体的健康和生活质量。公司目前正在执行战略转型，成为一家多元化的生物医学公司，扩展到高价值的治疗平台。这包括其蛋白质口服递送（POD™）平台，旨在实现生物药物的口服递送，主要候选药物 ORMD-0801（口服胰岛素）针对一个庞大且未被充分服务的糖尿病市场。</p>
</div><p>Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.</p>
<div class="lb-trans"><p>Lifeward 在美国、以色列和德国开展业务。有关 Lifeward 使命和产品组合的更多信息，请访问 GoLifeward.com。</p>
</div><p>Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.</p>
<div class="lb-trans"><p>Lifeward®、ReWalk®、ReStore®和 Alter G®是 Lifeward Ltd.及其附属公司的注册商标。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934 concerning Lifeward, Oramed, the strategic investment and partnership agreement with Oramed (collectively, the “Transactions”) and other matters. Such forward-looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like &#34;anticipate,&#34; &#34;assume,&#34; &#34;believe,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;future,&#34; &#34;will,&#34; &#34;should,&#34; &#34;would,&#34; &#34;seek&#34; and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others: Lifeward’s management team’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the perceived benefits or opportunities of the Transactions; expectations regarding the use of proceeds; the future operations of Lifeward, including research and development activities; the nature, strategy and focus of Lifeward; anticipated clinical drug development activities and related timelines, and other clinical results; the sufficiency of post-transaction resources to support the advancement of Lifeward’s pipeline through certain milestones and the time period over which Lifeward’s post-transaction capital resources will be sufficient to fund its anticipated operations; unexpected costs, charges or expenses resulting from the Transactions; potential adverse reactions or changes to business relationships resulting from the Transactions; and legislative, regulatory, political and economic developments; the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to achieve reimbursement from third-party payors, including CMS, for its products; the Company's limited operating history and its ability to leverage its sales, marketing and training infrastructure; the Company's expectations as to its clinical research program and clinical results; the Company's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; the Company's ability to obtain certain components of its products from third-party suppliers and its continued access to its product manufacturers; the Company’s ability to navigate any difficulties associated with moving production of its AlterG Anti-Gravity Systems to a contract manufacturer and transitioning the manufacturing of its ReWalk products to its in-house manufacturer; the Company's ability to improve its products and develop new products; the Company's compliance with medical device reporting regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on the Company's ability to market and sell its products; the Company's ability to gain and maintain regulatory approvals; the Company's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the Company's ability to use effectively the proceeds of its offerings of securities; and other factors discussed under the heading &#34;Risk Factors&#34; in the Company’s annual report on Form 10-K, as amended, for the year ended December 31, 2025 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</p>
<div class="lb-trans"><p>除了历史信息外，本新闻稿还包含根据 1995 年美国私人证券诉讼改革法案、1933 年美国证券法第 27A 条和 1934 年美国证券交易法第 21E 条的定义的前瞻性声明，涉及 Lifeward、Oramed、与 Oramed 的战略投资和合作协议（统称为 “交易”）及其他事项。这些前瞻性声明可能包括关于公司未来表现的预测以及其他非历史事实的声明，并且在某些情况下，可能会用 “预期”、“假设”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“可能”、“计划”、“潜在”、“预测”、“项目”、“未来”、“将”、“应该”、“会”、“寻求” 等类似词语或短语来识别。本新闻稿中包含的前瞻性声明基于管理层当前的预期，这些预期受到不确定性、风险和难以预测的情况变化的影响，其中许多超出了公司的控制范围。可能导致公司实际结果与前瞻性声明中所示结果显著不同的重要因素包括但不限于：Lifeward 管理团队对未来的期望、希望、信念、意图或战略，包括但不限于关于交易的感知利益或机会的声明；关于收益使用的预期；Lifeward 未来的运营，包括研究和开发活动；Lifeward 的性质、战略和重点；预期的临床药物开发活动及相关时间表，以及其他临床结果；交易后资源的充足性，以支持 Lifeward 的管道通过某些里程碑的推进，以及 Lifeward 交易后资本资源将足以资助其预期运营的时间段；交易所导致的意外成本、费用或支出；交易所导致的潜在不利反应或商业关系变化；以及立法、监管、政治和经济发展；ReWalk 7 个人外骨骼被医疗专业人士和患者接受的情况；与未来临床试验和临床开发过程、产品开发过程以及 FDA 监管提交审查和批准过程相关的不确定性；公司是否有足够的资金满足某些未来资本需求，这可能会影响公司开发和商业化现有及新产品的努力；公司维护和提升其声誉及产品市场接受度的能力；公司从第三方支付方（包括 CMS）获得其产品报销的能力；公司有限的运营历史及其利用销售、市场营销和培训基础设施的能力；公司对其临床研究计划和临床结果的预期；公司对未来增长的预期，包括其在现有地理市场增加销售和扩展到新市场的能力；公司从第三方供应商获得其产品某些组件的能力及其对产品制造商的持续访问；公司在将其 AlterG 抗重力系统的生产转移到合同制造商以及将其 ReWalk 产品的制造转移到内部制造商时所面临的任何困难的应对能力；公司改善其产品和开发新产品的能力；公司遵守医疗器械报告法规以报告涉及公司产品的不良事件的能力，这可能导致自愿纠正措施或强制措施，例如强制召回，以及这些不良事件对公司市场和销售其产品能力的潜在影响；公司获得和维持监管批准的能力；公司维护其知识产权的充分保护并避免侵犯他人知识产权的能力；网络安全攻击或公司 IT 系统的漏洞显著干扰其业务运营的风险；公司有效使用其证券发行收益的能力；以及在公司向 SEC 提交的 2025 年 12 月 31 日结束的年度报告（修订版）及随后提交或提供给 SEC 的其他文件中 “风险因素” 标题下讨论的其他因素。本新闻稿中所做的任何前瞻性声明仅在此日期有效。可能导致公司实际结果与此处所含声明不同的因素或事件可能会不时出现，公司无法预测所有这些因素。除法律要求外，公司没有义务公开更新任何前瞻性声明，无论是由于新信息、未来发展还是其他原因。</p>
</div><p>Contact:</p>
<div class="lb-trans"><p>联系方式：</p>
</div><p>Almog Adar</p>
<div class="lb-trans"><p>Almog Adar</p>
</div><p>Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官</p>
</div><p>Lifeward</p>
<div class="lb-trans"><p>Lifeward</p>
</div><p>E: media@golifeward.com</p>
<div class="lb-trans"><p>E: media@golifeward.com</p>
</div><p>E: ir@golifeward.com</p>
<div class="lb-trans"><p>E: ir@golifeward.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE56UXpOQ00zTlRrMU5ERTJJekl3TVRFeE9ETT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxNzQzNCM3NTk1NDE2IzIwMTExODM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTc4NDIxMmItN2VjZC00ODhlLWJkN2ItZmZkMjA1ZWFjMjY4LTEwMjI3NTYtMjAyNi0wNS0xMS1lbg==/tiny/Lifeward-Ltd-.png" alt="" original-src="https://ml.globenewswire.com/media/OTc4NDIxMmItN2VjZC00ODhlLWJkN2ItZmZkMjA1ZWFjMjY4LTEwMjI3NTYtMjAyNi0wNS0xMS1lbg==/tiny/Lifeward-Ltd-.png"/></p>

Lifeward 将在2026年5月15日公布 2026 年第一季度的财务业绩 | LFWD 股票新闻